Top

Published in:

01-10-2020 | Tyrosine Kinase Inhibitors | Original Article

Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management

Authors: Karen M. Fancher, Jeremy J. Pappacena

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2020

Abstract

Bruton’s tyrosine kinase (BTK) plays an essential role in B-cell development, differentiation and B-cell receptor (BCR) signaling. The use of Bruton’s tyrosine kinase inhibitors (BTKi) in the treatment of lymphoid malignancies has dramatically increased, owing to both impressive efficacy and ease of administration. However, BTKi have a range of drug–drug and drug–food interactions, which may alter drug efficacy and/or increase toxicity. Healthcare professionals should be aware of the probability of drug interactions with BTKi and make recommendations accordingly. In this article, we discuss the relevant drug–drug and drug–food interactions associated with ibrutinib, acalabrutinib, and zanubrutinib, and provide clinical practice recommendations for managing these interactions based on the available literature.

Roskoski R (2016) Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacol Res 113(Pt A):395–408PubMedCrossRef

Barf T, Covey T, Izumi R et al (2017) Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 363:240–252PubMedCrossRef

(2018) Imbruvica® (ibrutinib) [package insert]. Janssen Biotech, Inc., Horsham, PA

(2019) Calquence® (acalabrutinib) [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE

(2019) Brukinsa® (zanubrutinib) [package insert]. BeiGene USA, Inc., San Mateo, CA

Finnes HD, Chaffee KG, Call TG et al (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58(6):1376–1383PubMedCrossRef

Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20(12):1907–1912PubMedCrossRef

Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6(7):546–558PubMedCrossRef

National Cancer Institute Surveillance, Epidemiology and End Results Program. SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia. Available at https://seer.cancer.gov/statfacts/html/clyl.html. (Accessed 29 May 2020).

10.

Fu S, Wang M, Lairson DR et al (2017) Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas. Oncotarget 8(68):112516–112529PubMedPubMedCentralCrossRef

11.

Oza A, Rajkumar SV (2016) Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J 6:e391PubMedPubMedCentralCrossRef

12.

Khalil MO, Morton LM, Devesa SS et al (2014) Incidence of marginal zone lymphoma in the United States, 2001–2009 with a focus on primary anatomic site. Br J Haematol 165(1):67–77PubMedPubMedCentralCrossRef

13.

de Zwart L, Snoeys J, De Jong J et al (2016) Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther 100(5):548–557PubMedCrossRef

14.

de Jong J, Skee D, Murphy J et al (2015) Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect 3(4):e00156PubMedPubMedCentralCrossRef

15.

Bose P, Gandhi VV, Keating MJ (2016) Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol 1:1–12

16.

Mu S, Tang Z, Novotny W et al (2019) Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton’s tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer Chemother Pharmacol 85(2):391–399PubMedPubMedCentralCrossRef

17.

de Jong J, Haddish-Berhane N, Hellemans P et al (2018) The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemother Pharmacol 82(2):299–308PubMedCrossRef

18.

de Jong J, Hellemans P, Jiao J et al (2016) An open-label, sequential-design drug interaction study of the effects of omeprazole on the pharmacokinetics of ibrutinib in healthy adults. Blood 128:1588CrossRef

19.

Younes A, Sehn LH, Johnson P et al (2019) Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 37(15):1285–1295PubMedPubMedCentralCrossRef

20.

Kohrt HE, Sagiv-Barfi I, Rafiq F et al (2013) Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity. Blood 122:373CrossRef

21.

Woyach JA, Ruppert AS, Heerema NA et al (2018) Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202. American Society of Hematology Annual Meeting. Blood 132(S1):6–6CrossRef

22.

Wasserstrum Y, Raanani P, Kornowski R, Iakobishvili Z (2016) Concomitant treatment with ibrutinib and amiodarone causing reversible heart failure syndrome. Isr Med Assoc J 18(7):433–434PubMed

23.

Zhou D, Podoll T, Xu Y et al (2019) Evaluation of the drug-drug interaction potential of acalabrutinib and its active metabolite, ACP-5862, using a physiologically-based pharmacokinetic modeling approach. CPT Pharmacometrics Syst Pharmacol 8(7):489–499PubMedPubMedCentralCrossRef

24.

Izumi R, Pearson PG, Hamdy A et al (2017) CYP3A-mediated drug interaction profile of Bruton tyrosine kinase inhibitor, acalabrutinib. Blood 130:4996

25.

Golay J, Ubiali G, Introna M (2017) The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica 102(10):e400–e403PubMedPubMedCentralCrossRef

26.

VanDerMeid KR, Elliott MR, Baran AM et al (2018) Cellular cytotoxicity of next-generation CD20 monoclonal antibodies. Cancer Immunol Res 6(10):1150–1160PubMedCrossRef

27.

Chu CC, Pinney JJ, VanDerMeid KR et al (2019) Anti-CD20 therapy reliance on antibody-dependent cellular phagocytosis affects combination drug choice. Blood 134:682CrossRef

28.

Sharman JP, Banerji V, Fogliotto LM et al (2019) ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood 134(41):642

29.

Syed YY (2020) Zanubrutinib: first approval. Drugs 80(1):91–97PubMedCrossRef

30.

Li N, Sun Z, Liu Y et al (2015) BGB-311 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. Can Res 75(15):2597CrossRef

31.

Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37(3):213–255PubMedCrossRef

32.

Vaquero MP, Sanchez Muniz FJ, Jimenez Redondo S et al (2010) Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins. Nutr Hosp 25(2):193–206PubMed

33.

Center for Drug Evaluation and Research Application Number 210563orig1s000. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210563Orig1s000,210563Orig2s000ClinPharmR.pdf. (Accessed 29 May 2020)

34.

Waldron M, Winter A, Hill BT (2017) Pharmacokinetic and pharmacodynamic considerations in the treatment of chronic lymphocytic leukemia: ibrutinib, idelalisib, and venetoclax. Clin Pharmacokinet 56(11):1255–1266PubMedCrossRef

35.

Center for Drug Evaluation and Research Application Number 210259orig1s000. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210259Orig1s000MultidisciplineR.pdf. (Accessed 29 May 2020)

36.

Foster BC, Vandenhoek S, Hana J et al (2003) In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 10(4):334–342 PubMedCrossRef

37.

Sprouse AA, van Breemen RB (2016) Pharmacokinetic Interactions between drugs and botanical dietary supplements. Drug Metab Dispos 44(2):162–171PubMedPubMedCentralCrossRef

38.

Memorial Sloan Kettering Cancer Center. About Herbs, Botanicals and Other Products. Available at https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs. (Accessed 29 May 2020)

39.

Chai KL, Rowan G, Seymour JF et al (2017) Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymphoma 58(12):2811–2814PubMedCrossRef

40.

Kamel S, Horton L, Ysebaert L et al (2015) Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 29(4):783–787PubMedCrossRef

41.

Shatzel JJ, Olson SR, Tao DL et al (2017) Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 15(5):835–847PubMedPubMedCentralCrossRef

42.

Boriani G, Corradini P, Cuneo A et al (2018) Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol 36(4):624–632PubMedCrossRef

43.

Stephens DM, Byrd JC (2019) How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133(12):1298–1307PubMedPubMedCentralCrossRef

44.

Chen LS, Bose P, Cruz ND et al (2018) A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249–2259PubMedPubMedCentralCrossRef

45.

Center for Drug Evaluation and Research Application Number 213217orig1s000. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000MultidisciplineR.pdf. (Accessed 20 July 2020)

Title: Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management
Authors: Karen M. Fancher
Jeremy J. Pappacena
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Acalabrutinib
Ibrutinib
Zanubrutinib
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2020
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-020-04137-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer

Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer

CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

Keynote webinar | Spotlight on antibody–drug conjugates in cancer